Albertsons Companies (ACI) Q1 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2025 earnings summary
9 Jan, 2026Executive summary
Identical sales grew 2.8% year-over-year, with digital sales up 25% and loyalty members increasing 14% to 47.3 million.
Net sales and other revenue rose 2.5% to $24.88 billion, driven by digital and pharmacy growth.
Adjusted EBITDA was $1.11 billion and adjusted EPS was $0.55, both down year-over-year.
Strategic priorities include digital engagement, Media Collective expansion, customer value, technology modernization, and productivity.
The company invested in technology, store remodels, and new brands, while returning over $400 million to shareholders via dividends and share repurchases.
Financial highlights
Gross margin rate declined to 27.1% from 27.8% year-over-year, mainly due to investments in value and higher digital sales costs.
Adjusted EBITDA was $1.11 billion (4.5% of revenue), down from $1.18 billion (4.9%) year-over-year.
Selling and administrative expense rate improved by 63 bps, aided by productivity and lower merger costs.
Operating income was $449 million, down from $460 million year-over-year.
Interest expense decreased to $141.8 million; effective tax rate rose to 24.1%.
Outlook and guidance
FY2025 identical sales growth guidance raised to 2-2.75% (from 1.5-2.5%).
Adjusted EBITDA guidance unchanged at $3.8-$3.9 billion; adjusted EPS guidance unchanged at $2.03-$2.16.
Expect gradual acceleration in sales in the second half of 2025, with productivity tailwinds offsetting margin investments.
Capital expenditures expected at $1.7-$1.9 billion.
Management expects sufficient liquidity for the next 12 months, with estimated needs of $5.5 billion.
Latest events from Albertsons Companies
- Q3 delivered solid sales and digital growth, but faces post-merger litigation and margin pressure.ACI
Q3 202410 Jan 2026 - Q3 2025 saw 2.4% identical sales growth, strong digital gains, and major capital actions.ACI
Q3 20257 Jan 2026 - Q2 2025 saw 2.0% revenue growth, higher net income, and a $750M share buyback announcement.ACI
Q2 20257 Jan 2026 - Q4 delivered strong digital and pharmacy growth, but margin pressure tempers 2025 optimism.ACI
Q4 202419 Dec 2025 - Board recommends against all shareholder proposals; focus remains on digital growth and ESG impact.ACI
Proxy Filing1 Dec 2025 - Annual meeting to vote on directors, auditor, and pay, with focus on merger, governance, and ESG.ACI
Proxy Filing1 Dec 2025 - Annual proxy statement outlines voting items and confirms standard shareholder meeting.ACI
Proxy Filing1 Dec 2025 - Definitive additional proxy materials filed for shareholder voting, with no fee required.ACI
Proxy Filing1 Dec 2025 - All directors attended at least 75% of board and committee meetings in fiscal 2024.ACI
Proxy Filing1 Dec 2025